NASDAQ
05.12.25 | 22:00
25,440 US-Dollar
+0,71 % +0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.10. | Arcus Biosciences stock falls after pricing $250 million public offering | 3 | Investing.com | ||
| 31.10. | Arcus Biosciences prices $250M offering | 2 | Seeking Alpha | ||
| 31.10. | Arcus Biosciences prices $250 million public offering at $18.25 per share | 2 | Investing.com | ||
| 30.10. | Hedge Fund and Insider Trading News: Paul Tudor Jones, Berkshire Hathaway, Soros Fund Management, Citadel Investment Group, LMR Partners, Iridium Communications Inc (IRDM), Arcus Biosciences Inc (RCUS), and More | 10 | Insider Monkey | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.10. | Arcus Biosciences launches public offering of common stock | 1 | Investing.com | ||
| 29.10. | Analyst Expectations For Arcus Biosciences' Future | 2 | Benzinga.com | ||
| 28.10. | Arcus Biosciences: EPS übertrifft Schätzungen um 0,01 $ - Umsatz besser als erwartet | 2 | Investing.com Deutsch | ||
| 28.10. | Arcus Biosciences GAAP EPS of -$1.27 beats by $0.06, revenue of $26M beats by $5.75M | 1 | Seeking Alpha | ||
| 28.10. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.10. | Arcus Biosciences stock rises after strong gastric cancer survival data | 1 | Investing.com | ||
| 13.10. | Arcus Biosciences-Aktie steigt nach starken Überlebensdaten bei Magenkrebs | 1 | Investing.com Deutsch | ||
| 13.10. | Arcus Biosciences rises on results from domvanalimab cancer study | 1 | Seeking Alpha | ||
| 13.10. | Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months | 24 | Benzinga.com | ||
| 13.10. | Arcus Biosciences to present promising gastric cancer survival data | 1 | Investing.com | ||
| 07.10. | Truist Securities raises Arcus Biosciences stock price target on casdatifan potential | 1 | Investing.com | ||
| 07.10. | Casdatifan-Potenzial: Truist Securities hebt Kursziel für Arcus Biosciences an | 1 | Investing.com Deutsch | ||
| 07.10. | How Arcus Biosciences Aims To Take On Merck In Cancer Treatment | 9 | Investor's Business Daily | ||
| 06.10. | Why Is Arcus Biosciences Stock Trading Higher On Monday? | 1 | Benzinga.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 33,235 | +0,38 % | Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics | ||
| INTELLIA THERAPEUTICS | 8,110 | -1,58 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| XOMA ROYALTY | 26,600 | +3,91 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc | EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,554 | +1,23 % | Telix Opens First Cyclotron Facility In Asia-Pacific | CANBERA (dpa-AFX) - Telix Pharmaceuticals Ltd. (TLX, TLPPF, TLX.AX), on Friday announced officially opened Telix Manufacturing Solutions in Yokohama, marking its first cyclotron facility in... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,090 | -6,30 % | Beam Therapeutics: Positive Studiendaten zur Sichelzelltherapie treiben Aktie an | ||
| ROCKET PHARMACEUTICALS | 2,820 | -0,95 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | ||
| OUTLOOK THERAPEUTICS | 1,713 | -2,95 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD | Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,780 | +3,02 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| ROIVANT SCIENCES | 18,230 | +1,19 % | Roivant Sciences: Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,800 | +2,65 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| ANNOVIS BIO | 3,945 | +0,90 % | Annovis Bio Inc.: Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group | ||
| ADVERUM BIOTECHNOLOGIES | 3,460 | -3,35 % | Adverum Biotechnologies, Inc. - 8-K, Current Report | ||
| REIN THERAPEUTICS | 1,360 | -2,16 % | Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 4,010 | +11,39 % | Quince Therapeutics, Inc.: Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference | Phase 3 NEAT enrollment momentum continues with 99 total participants enrolled to date
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,270 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,71 % bei einem Aktienkurs von 25,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.